Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy

Inclusion Criteria: * Diagnosis of malignant disease of any stage; (stage I through stage IV) * No prior history of chemotherapy for any malignancy * Scheduled to receive intravenous HEC (highly emetogenic chemotherapy) (either cisplatin-containing regimen or doxorubicin and cyclophosphamide \[AC\]); cisplatin, given on a single day, at a dose of \>= 70 mg/m\^2, with or without other chemotherapy agent(s) OR doxorubicin (60 mg/m\^2) plus cyclophosphamide (600 mg/m\^2) * No nausea or vomiting =\< 24 hours prior to registration * Negative pregnancy test (serum or urine) done =\< 7 days prior to registration, for women of childbearing potential only \* A female of childbearing potential is a sexually mature female who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months) * No known diagnosis of dementia; patients with stable treated brain metastases are eligible to participate * No known history of central nervous system (CNS) disease (e.g. seizure disorder) * No treatment with another antipsychotic agent such as olanzapine, risperidone, quetiapine, clozapine, phenothiazine or butyrophenone =\< 30 days prior to registration * No chronic phenothiazine administration as an antipsychotic agent (patients may receive prochlorperazine and other phenothiazines as rescue anti-emetic therapy but not within 24 hours prior to…